Global InformationArenicin information
| Arenicin | |
|---|---|
| Identifiers | |
| Symbol | undefined |
| TCDB | 1.C.81 |
| OPM superfamily | 203 |
| OPM protein | 2jni |
Arenicins are a group of antimicrobial peptides being studied to combat Gram-negative bacteria.
The arenicin family consists of three different peptides: arenicin-1, arenicin-2, and the most recently discovered, arencin-3.[1]
Given the growing acquisition of multidrug resistance among bacterial pathogens, particularly in Gram-negative bacteria, the development of arenicin as a novel drug treatment has been under way. Arenicin-3 has been of particular interest in the fight against urinary tract infections caused by E. coli strains. It is also being developed with the intention of treating hospital acquired infections. In both applications, there are two proposed modes of action by which arenicin-3 interacts with the bacteria.[2]
Adenium Biotech currently remains in the preclinical testing period of their product, arenicin-3. Toxicology, drug efficacy, and other information have yet to be determined with further research completed in clinical settings. However, with Gram-negative bacteria causing 65% of hospital-acquired infections, the commercial market for arenicin is large.[3]
- ^ Neve, S., Raventós, D., et al. "NZ17074 : An Arenicin-3 variant found by HTS screening of yeast libraries" Archived October 29, 2013, at the Wayback Machine. Novozymes A/S. Copenhagen: Adenium Biotech, Web. 21 Nov. 2012.
- ^ Adenium Biotech Aps. EP2509617A1, 2012, "Arenicin-3 for use in the treatment of urinary tract infections"
- ^ "Adenium Biotech" Archived October 29, 2013, at the Wayback Machine. Novozymes A/S. Copenhagen: Adenium Biotech, Web. 21 Nov. 2012.